RxDoctor Payments Data

Alan Twer, MD

Ophthalmology · Philadelphia, PANPI 1659319382

Payments from drug & device makers

$928in general payments, 2019–2025

Across 36 payments — averaging $25.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$341
  • AbbVie$132
  • Oyster Point Pharma, Inc.$97
  • Johnson & Johnson Surgical Vision, Inc.$74
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$57
  • Alcon$45
  • plus $181 from 8 others

What the payments were for

  • Food & beverage$89296%
  • Gifts$374%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$928 in reported general payments places this provider in the 40th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$96,720
Medicare patients
420
Services billed
844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine48$59,654
LumiganBimatoprost46$29,944
Cyclosporine34$21,035
VyzultaLatanoprostene Bunod24$13,480
MieboPerfluorohexyloctane/Pf16$12,180
SimbrinzaBrinzolamide/Brimonidine Tart23$6,197
Difluprednate63$5,549
Brimonidine Tartrate20$4,426
Timolol Maleate50$4,107
Bromfenac Sodium31$3,901
Loteprednol Etabonate21$3,894
Travoprost23$3,502
CombiganBrimonidine Tartrate/Timolol13$3,286
Latanoprost210$3,160
MoxifloxacinMoxifloxacin Hcl134$2,997

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$132$92,883107 claims
Bausch & Lomb Americas Inc.Vyzulta, Miebo$341$25,66040 claims
AlconSimbrinza$45$6,19723 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$57$3,89421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →